WYOMISSING, Pennsylvania, Aug. 29 2016—
Adhezion Biomedical, LLC announces the completion of a long-term supply agreement with Pfizer Inc. (NYSE:PFE) for the exclusive distribution rights of Adhezion’s product family of 2-octyl cyanoacrylate topical skin adhesives in the United States and its territories and possessions. The product line includes SurgiSeal®, SurgiSeal Stylus® and SurgiSeal Twist® topical skin adhesives. SURGISEAL is intended for topical applications only to hold closed easily approximated skin edges of wounds from surgical incisions, including punctures from minimally invasive surgery, and simple, thoroughly cleansed, trauma induced lacerations. SURGISEAL may be used in conjunction with, but not in place of, deep dermal sutures.
"It is my pleasure to announce that the SURGISEAL product family of brands can now be purchased from Pfizer Inc., in the United States and its territories and possessions. Pfizer is one of the world's premier biopharmaceutical companies, and this partnership offers strong support for our business," said Pete Molinaro, Chairman & CEO of Adhezion Biomedical, LLC.About Adhezion Biomedical LLC
Adhezion Biomedical is a privately held medical device company based in Wyomissing, PA. Adhezion is committed to developing and manufacturing medical cyanoacrylate products used in the treatment of wound closure, wound management, intravenous device securement and infection prevention. To learn more about Adhezion and its products, visit www.adhezion.com.
Exhibitor Data Sheet